Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS1410 in Primary Aldosteronism
NCT07550465Phase 2Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of QLS1410 in primary aldosteronism (PA), sponsored by Qilu Pharmaceutical. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
QLS1410
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on NCT07550465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07550465.